PLOD1 and osteoporosis: Given the preferential stimulation of LH secretion in response to kisspeptin in humans (Dhillo et al., 2005, 2007; George et al., 2011, 2012), kisspeptin antagonists might potentially result in relative sparing of FSH compared with LH, which might reduce or prevent the unwanted side effects of estrogen deficiency, such as vasomotor symptoms and risk of osteoporosis, associated with GnRH analogue administration.